| Primary |
| Tuberculosis |
47.8% |
| Pulmonary Tuberculosis |
18.2% |
| Pericarditis Tuberculous |
6.5% |
| Mycobacterium Avium Complex Infection |
4.9% |
| Lymph Node Tuberculosis |
3.6% |
| Peritoneal Tuberculosis |
2.0% |
| Tuberculous Meningitis |
2.0% |
| Extrapulmonary Tuberculosis |
1.6% |
| Miliary Tuberculosis |
1.6% |
| Pericarditis |
1.6% |
| Product Used For Unknown Indication |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Tuberculosis Bladder |
1.6% |
| Atypical Mycobacterial Lymphadenitis |
1.2% |
| Tuberculous Peritonitis |
1.2% |
| Breast Cancer Metastatic |
0.8% |
| Lung Infection |
0.8% |
| Epilepsy |
0.4% |
| Hyperuricemia |
0.4% |
| Pneumonia |
0.4% |
|
| Drug Reaction With Eosinophilia And Systemic Symptoms |
31.3% |
| Renal Failure Acute |
10.4% |
| Vomiting |
10.4% |
| Renal Transplant Failure |
6.3% |
| Paradoxical Drug Reaction |
4.2% |
| Toxicity To Various Agents |
4.2% |
| Tuberculoma Of Central Nervous System |
4.2% |
| White Blood Cell Count Increased |
4.2% |
| Blindness |
2.1% |
| Dermatitis Exfoliative |
2.1% |
| Erythema Multiforme |
2.1% |
| Hepatotoxicity |
2.1% |
| Hypersensitivity Vasculitis |
2.1% |
| Liver Function Test Abnormal |
2.1% |
| Meningitis |
2.1% |
| Mitochondrial Encephalomyopathy |
2.1% |
| Mitochondrial Toxicity |
2.1% |
| Multi-organ Failure |
2.1% |
| Muscular Weakness |
2.1% |
| Myalgia |
2.1% |
|
| Secondary |
| Tuberculosis |
27.8% |
| Pulmonary Tuberculosis |
16.8% |
| Mycobacterium Avium Complex Infection |
7.4% |
| Tuberculosis Of Eye |
7.4% |
| Lymph Node Tuberculosis |
5.8% |
| Hiv Infection |
5.6% |
| Product Used For Unknown Indication |
5.1% |
| Drug Use For Unknown Indication |
4.3% |
| Meningitis Tuberculous |
3.9% |
| Pericarditis Tuberculous |
2.1% |
| Intermediate Uveitis |
2.0% |
| Choroiditis |
1.6% |
| Retinal Vasculitis |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Uveitis |
1.4% |
| Atypical Mycobacterial Lymphadenitis |
1.2% |
| Peritoneal Tuberculosis |
1.2% |
| Atypical Mycobacterial Infection |
1.2% |
| Antiretroviral Therapy |
1.1% |
| Tuberculous Pleurisy |
1.0% |
|
| Drug Reaction With Eosinophilia And Systemic Symptoms |
12.7% |
| Rash Maculo-papular |
7.6% |
| Vomiting |
7.6% |
| Tuberculoma Of Central Nervous System |
7.0% |
| Pyrexia |
6.4% |
| Rash Erythematous |
5.1% |
| Hepatitis Toxic |
4.5% |
| Renal Failure Acute |
4.5% |
| Transplant Dysfunction |
4.5% |
| White Blood Cell Count Increased |
4.5% |
| Choroiditis |
3.8% |
| Hepatotoxicity |
3.8% |
| Intermediate Uveitis |
3.8% |
| Paradoxical Drug Reaction |
3.8% |
| Rash |
3.8% |
| Uveitis |
3.8% |
| Renal Tubular Necrosis |
3.2% |
| Respiratory Failure |
3.2% |
| Sepsis |
3.2% |
| Thrombocytopenia |
3.2% |
|
| Concomitant |
| Tuberculosis |
28.6% |
| Pulmonary Tuberculosis |
17.7% |
| Product Used For Unknown Indication |
11.7% |
| Hiv Infection |
10.9% |
| Mycobacterium Avium Complex Infection |
4.3% |
| Mycobacterial Infection |
2.7% |
| Antibiotic Prophylaxis |
2.5% |
| Drug Use For Unknown Indication |
2.3% |
| Disseminated Tuberculosis |
2.3% |
| Atypical Mycobacterial Infection |
2.1% |
| Ankylosing Spondylitis |
2.1% |
| Immunosuppression |
2.0% |
| Bone Tuberculosis |
1.9% |
| Rheumatoid Arthritis |
1.7% |
| Meningitis Tuberculous |
1.4% |
| Immunosuppressant Drug Therapy |
1.3% |
| Lymph Node Tuberculosis |
1.2% |
| Pain |
1.2% |
| Gastroenteritis |
1.0% |
| Oesophageal Carcinoma |
1.0% |
|
| Vomiting |
14.2% |
| Toxic Epidermal Necrolysis |
12.9% |
| Weight Decreased |
11.0% |
| Hepatitis Toxic |
5.8% |
| Transplant Rejection |
5.2% |
| Pneumonitis |
4.5% |
| Sudden Death |
4.5% |
| Tuberculosis |
4.5% |
| Neutropenia |
3.9% |
| Rash Erythematous |
3.9% |
| Thrombocytopenia |
3.9% |
| Pyrexia |
3.2% |
| Renal Failure Acute |
3.2% |
| Sepsis |
3.2% |
| Vasculitis Cerebral |
3.2% |
| Drug Interaction |
2.6% |
| Interstitial Lung Disease |
2.6% |
| Pneumonia Aspiration |
2.6% |
| Respiratory Failure |
2.6% |
| Uveitis |
2.6% |
|
| Interacting |
| Tuberculosis |
48.6% |
| Pulmonary Tuberculosis |
28.6% |
| Breast Cancer Metastatic |
8.6% |
| Hiv Infection |
5.7% |
| Hyperlipidaemia |
5.7% |
| Depression |
2.9% |
|
| Drug Interaction |
20.0% |
| Hepatitis B Surface Antigen Positive |
20.0% |
| Muscular Weakness |
20.0% |
| Polyneuropathy |
20.0% |
| Vomiting |
20.0% |
|
